AstraZeneca is a global, science-led, patient-focused pharmaceutical company led biopharmaceutical business one of only a handful of companies to span the entire life-cycle of a medicine from research and development to manufacturing and supply, and the global commercialisation of primary care and specialty care medicines. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
We are focused on creating genuinely innovative medicines and improving access to them. In this way, we deliver the greatest benefit to patients, healthcare systems and societies globally.
Our primary focus is on five areas of healthcare: Oncology; Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology, Vaccines & Immune Therapies and Rare diseases. We operate in more than 100 countries and our innovative medicines are used by millions of patients worldwide. We are committed to operating sustainably, in a way that recognises the interconnection between business growth, the needs of society and the limitations of our planet. We are committed to operating with integrity and high ethical standards across all our activities.
As part of our efforts to bring innovative medicines to patients, we are focusing a substantial amount of our research to oligonucleotide (ON) based therapeutics via collaborations as well as internal research activities. In the recent years, we have built internal expertise in chemistry, delivery of ON therapeutics as well as understanding the mechanisms of delivery and uptake into specific cells and tissues. We are uniquely positioned to develop cutting-edge nucleotide-based therapeutics, and we are growing a differentiated pipeline to address targeting to specific cells and tissues to realise the full potential of nucleotide-based therapeutics. We have currently 5 nucleotide-based drug compounds in clinical phase (PhI-III).